Multi-Center Trial of Baclofen for the Treatment of Cocaine Dependence
Baclofen
+ Placebo
Mental Disorders+1
+ Substance-Related Disorders
+ Cocaine-Related Disorders
Treatment Study
Summary
Study start date: June 1, 2004
Actual date on which the first participant was enrolled.Double-blind, placebo-controlled, parallel design trial of baclofen for the treatment of cocaine dependence
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.160 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Treatment Study
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Any sex
Biological sex of participants that are eligible to enroll.From 18 to 99 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Criteria
Inclusion Criteria: * Subject must have DSM-IV diagnosis of cocaine dependence. * Subject must be seeking treatment for cocaine dependence. * Be be able to verbalize understanding of consent form, provide written consent and verbalize willingness to complete study procedures. Exclusion Criteria: * Please contact site for more information.
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.2 intervention groups are designated in this study
50% chance of being blinded to the placebo group
Treatment Groups
Group I
Active ComparatorGroup II
PlaceboStudy Objectives
Primary Objectives
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 8 locations
Torrance Site
Torrance, United StatesDenver VA Medical Center
Denver, United StatesVA Maryland Healthcare System
Baltimore, United States